Your session is about to expire
← Back to Search
Monoclonal Antibodies
LM-108 for Solid Tumors
Phase 1 & 2
Waitlist Available
Research Sponsored by LaNova Medicines Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 126 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called LM-108, alone or with another drug, in patients with advanced solid tumors. The goal is to see if these drugs are safe and effective. The other drug helps the immune system fight cancer and has been approved for the treatment of various cancers since 2014.
Eligible Conditions
- Advanced Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 126 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~126 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
AEs
DLT
Incidence of clinical significant in laboratory examinations
+1 moreSecondary study objectives
AUC
CLss
Cmax
+9 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: LM-108 Dose ExpansionExperimental Treatment1 Intervention
Drug: LM-108 Administered intravenously
Group II: LM-108 Dose EscalationExperimental Treatment1 Intervention
Drug: LM-108 Administered intravenously
Group III: LM-108 Combination Dose ExpansionExperimental Treatment2 Interventions
Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
Group IV: LM-108 Combination Dose EscalationExperimental Treatment2 Interventions
Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
Find a Location
Who is running the clinical trial?
LaNova Medicines LimitedLead Sponsor
10 Previous Clinical Trials
1,198 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have received any live vaccines within the past 28 days.You have a mental health condition or disorder.You have another type of cancer that is currently being treated and may require ongoing treatment.You have a history of a weakened immune system.You currently use inhalers for asthma or other respiratory conditions.You have severe, uncontrolled pain from your tumor.You have a serious heart or blood vessel condition.You have fluid buildup around your lungs, heart, or abdomen that needs to be drained regularly and is not under control.You have a history of an autoimmune disease.You are able to perform daily activities without much difficulty.Any side effects from previous cancer treatment have not fully resolved or are still causing mild symptoms.You must have at least one visible tumor that can be measured using specific guidelines (RECIST v1.1).Your organs and bone marrow must be functioning properly based on recent lab tests taken within a week before starting the study.You have a known condition where the central nervous system (brain and spinal cord) is affected.You have a type of cancer that has come back or is not responding to standard treatments. Your doctor has confirmed this through a biopsy or other testing.
Research Study Groups:
This trial has the following groups:- Group 1: LM-108 Dose Escalation
- Group 2: LM-108 Combination Dose Escalation
- Group 3: LM-108 Combination Dose Expansion
- Group 4: LM-108 Dose Expansion
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Solid Tumors Patient Testimony for trial: Trial Name: NCT05255484 — Phase 1 & 2
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger